

PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

^a Gastroenterology and Hepatology Department, Poitiers University Hospital, Poitiers, France, ^b Gastroenterology and Hepatology Department, Oscar Lambret Center, Lille, France, ^d Fédération Francophone de Cancérologie Digestive, EPICAD INSERM LNC-UMR 1231, Bourgogne Franche-Comté University, Dijon, France, ^e Digestive Oncology Department, A. Lacassagne Center, Nice, France, ^f Gastroenterology and Digestive Oncology Department, Saint Louis Hospital, Reims, France, ^g Gastroenterology Department, Saint Louis Hospital, Paris, ^j Diaconesses Croix Simon hospital, Paris, France, ^a Gastroenterology Department, Saint Etienne, France, ^a Gastroenterology Department, Saint Etienne, France, ^a Medical Oncology Department, Institute Mutualiste Montsouris, Paris, France

INTRODUCTION


- checkpoint inhibitors (ICI) have Immune demonstrated their efficacy as first-line treatment of in advanced gastric/gastro-oesphageal junction (GEJ) with PD-L1 combined positive score (CPS) \geq 5.
- Efficacy of 2nd line chemotherapy in advanced gastric/GEJ adenocarcinoma remains limited based on paclitaxel, ramucirumab, irinotecan alone or combined with 5FU.
- No study up until now has evaluated the efficacy of ICIs combined with chemotherapy as 2nd line treatment of advanced gastric/GEJ adenocarcinoma.

DURIGAST PRODIGE 59 is a randomized, multicenter, phase II study designed to assess the efficacy and safety of the combination of **FOLFIRI plus durvalumab** (anti-PD-L1) (FD) versus **FOLFIRI plus durvalumab and tremelimumab** (anti-CTLA-4) (FDT).

Key eligibility criteria were:

- advanced gastric/GEJ adenocarcinoma
- platinum-based first-line chemotherapy
- ECOG performance status (PS) 0 or 1

The primary endpoint is progression-free survival (PFS) at 4 months, which was expected to be 70% (H_0 :50%). With an α risk of 5%, a power of 85% and 5% of non-evaluable patients, 47 evaluable patients were needed by arm. Secondary endpoints included safety, overall survival (OS) and quality of life.



- To assess the safety of the combination of FOLFIRI + Durvalumab + Tremelimumab combination in 11 patients
- 63.6% experienced at least one grade 3-4 adverse events related to the treatment, most frequently neutropenia (36.4%).
- **Only one immune-related adverse event** (grade 2 hyperthyroidism).
- One seizure epilepsy related to a brain metastasis was observed but was not related by the investigator to the treatment (Independent Data Monitoring Committee recommended brain imaging at inclusion for the randomised phase II).

David Tougeron^a, Laetitia Dahan^b, Farid El Hajbi^c, Karine Le Malicot^d, Ludovic Evesque^e, Thomas Aparicio^f, Olivier Bouche^g, Nathalie Bonichon Lamichhane^h, Benoist Chibaudelⁱ, Antoine Angelergues^j, Anaïs Bodere^k, Jean-Marc Phelip^I, May Mabro^m, Pascal Artruⁿ, Christophe Louvet^o

PATIENTS AND METHODS

CHARACTERISTICS

48 patients were randomized in each arm.

• Primary endpoint was analysed on the modified intent-to-treat population (patients with at least one dose of treatment): 47 in arm A and 45 in arm B.

Table 1. Patients characteristics

Liver Lung Perit Lymp Prior regim Douk Triple

bles	All patients n=92	Folfiri + Durvalumab n=47	Folfiri + Durvalumab + Tremelimumab n=45
years, range)	60.0 [24.7-83.3]	59.9 [28.2-83.3]	60.2 [24.7-82.6]
ale (n, %)	28 (30.4%)	14 (29.8%)	14 (31.1%)
6 performance status (n, %)***	31 (33.7%) 61 (66.3%)	11 (23.4%) 36 (76.6%)	20 (44.4%) 25 (55.6%)
Mass Index (kg/m ² , range)	27.1 [16.6-48.4]	25.5 [17.8-39.1]	27.6 [16.6-48.4]
ary tumour site (n, %) ro-esophageal junction nach	49 (53.3%) 43 (46.7%)	27 (57.4%) 20 (42.6%)	22 (48.9%) 23 (51.1%)
our subtype (Lauren ification) (n, %) stinal type use type ers/Unknown	46 (50.0%) 36 (39.1%) 10	22 (46.8%) 20 (42.6%) 5	24 (53.3%) 16 (35.6%) 5
osatellite instability cient icient iown	4 (4.3%) 84 (91.3%) 4	3 (6.4%) 40 (85.1%) 4	1 (2.2%) 44 (97.8%) 0
y of metastatic disease (n, %) achronous hronous	32 (34.8%) 60 (65.2%)	17 (36.2%) 30 (63.8%)	15 (33.3%) 30 (66.7%)
ction of primary tumour (n, %)	67 (72.8%) 25 (27.2%)	34 (72.3%) 13 (27.7%)	33 (73.3%) 12 (26.7%)
of metastases (n, %) g toneal carcinomatosis ph nodes	37 (40.2%) 18 (19.6%) 33 (35.9%) 36 (39.1%)	19 (40.4%) 9 (19.1%) 16 (34.0%) 19 (40.4%)	18 (40.0%) 9 (20.0%) 16 (34.0%) 17 (37.8%)
first-line chemotherapy nen (n, %) blet regimen et regimen	47 (63.5%) 25 (33.8%)	28 (73.7%) 9 (23.7%)	19 (52.8%) 16 (44.4%)




Table 2. Safety

Bras A - FOI FIRI + DURVAI UMAB 47

Bras B - FOI FIRI + DURVALLIMAB + TREMELIMUMAB


No at Risk


Variables		firi + Durvalumab n=47 Folfiri + Durvalumab + Tremelimumab n=45		
	Grade 1-2	Grade 3-4-5	Grade 1-2	Grade 3-4-5
Patients with at least one adverse event	43 (93.5%)	22 (47.8%)	42 (91.3%)	22 (47.8%)
Endocrine disorders Hyperthyroidism Hypothyroidism	4 (8.7%) 1 (2.2%) 3 (6.5%)	-	10 (21.7%) 1 (2.2%) 3 (6.5%)	-
Gastrointestinal disorders Diarrhea Colitis Vomiting	37 (80.4%) 23 (50.0%) - 12 (26.1%)	5 (10.9%) 1 (2.2%) 2 (4.3%) 3 (6.5%)	40 (87.0%) 30 (65.2%) - 14 (30.4%)	5 (10.9%)
Investigations AST/ALT increase Neutrophil decrease Lymphocyte decrease	30 (65.2%) 6 (13.0%) 14 (30.4%) 10 (21.7%)	10 (21.7%) 7 (15.2%) 1 (2.2%)	29 (63.0%) 7 (15.2%) 9 (19.6%) 14 (30.4%)	14 (30.4%)
General disorder Fatigue	25 (54.3%) 25 (54.3%)	9 (19.6%) 8 (17.4%)	27 (58.7%) 25 (54.3%)	



DISEASE-FREE AND OVERALL SURVIVAL

	Folfiri + Durvalumab	FOLFIRI + durvalumab + tremelimumab
onths [90% CI]	44.7% [32.2-57.7]	55.6% [42.3-68.3]
6 [95%CI]	3.8 [3.0-7.4] months	5.4 [2.9-6.4] months
ntol rate	67.4%	68.9%
response	5.1 months	4.3 months
[95%CI]	13.3 [6.6-15.6] months	9.5 [7.1-11.3] months





CONCLUSION

- Acceptable safety profile of immune checkpoint inhibitors plus FOLFIRI in 2nd line treatment for advanced gastric/GEJ adenocarcinoma.
- Primary endpoint was not meet but both arms demonstrated a clinically relevant efficacy never before achieved.
- Ancillary studies are ongoing to identify predictive biomarkers of efficacy (PD-L1 status, immune scores, tumor mutation burden and microbiota).

Trial registration: NCT03959293 david.tougeron@chu-poitiers.fr